Portal Hypertension SIG: Mechanisms of Regression of Portal Hypertension
Recorded On: 11/09/2018
There has been no new drug class in the treatment of portal hypertension in over 25 years. But recent advancements in our understanding of the pathophysiology of portal hypertension and its potential regression have informed development of oninvasive biomarkers and revealed exciting new targets for therapy. This program will discuss key developments in the basic biology of portal hypertension and how this knowledge is being applied to develop novel biomarkers and therapeutic approaches for portal hypertension.
Jonathan Fallowfield
Jordi Gracia-Sancho
Annalisa Berzigotti
Annalisa Berzigotti graduated in Medicine in Bologna, Italy, where she also obtained the title of specialist in Internal Medicine and a Doctorate in ultrasound in medicine. She expanded her knowledge in hepatology at the Hepatic hemodynamic Laboratory of the Liver Unit of the Hospital Clinic, University of Barcelona, Spain, where she obtained a Doctorate in hepatology. In December 2014 she joined the hepatology group of the Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Switzerland. Since March 2021 she is chief of the liver group and ad interim clinic director at the Department of Visceral Surgery and Medicine, Bern University Hospital. Annalisa Berzigotti has been member of the Governing Board of the European Association for the Study of the Liver in 2016-2019. Since 2022 she is Liver Representative at the United European Gastroenterology (UEG) Council. She is Associate Editor of the Journal of Hepatology and of Seminars in Liver Disease. Her main research interests include portal hypertension and non-invasive assessment of liver disease.
Ramon Bataller
Guadalupe Garcia-Tsao
Guadalupe Garcia-Tsao, MD, FAASLD is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.